ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
COVID vaccines

Shionogi and Daiichi Sankyo join hunt for omicron vaccine

Japanese drugmakers prepare to modify shots under development

Vaccine makers worldwide are scrambling to develop inoculations against the new omicron coronavirus variant.   © Reuters

TOKYO -- Japanese drugmakers Shionogi and Daiichi Sankyo look to ensure that their vaccines under development will be effective against the new omicron variant of the coronavirus.

Shionogi is considering making an active vaccine ingredient based on the omicron virus' genetic information. The company has been developing a vaccine against previous coronavirus variants which will soon enter final-stage clinical trials, with plans to go on the market by March.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more